[
  {
    "ts": null,
    "headline": "Archer Daniels Midland Co. stock outperforms competitors on strong trading day",
    "summary": "Archer Daniels Midland Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=37bce0508a917fef8112fd276f7081451e70754468a358efc08b2c70888a4a13",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758042000,
      "headline": "Archer Daniels Midland Co. stock outperforms competitors on strong trading day",
      "id": 136811562,
      "image": "",
      "related": "ADM",
      "source": "MarketWatch",
      "summary": "Archer Daniels Midland Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=37bce0508a917fef8112fd276f7081451e70754468a358efc08b2c70888a4a13"
    }
  },
  {
    "ts": null,
    "headline": "ClostraBio Announces Key Milestones: Board Appointment of Industry Veteran Scott Ravech and Publication of CLB101™ Safety Data",
    "summary": "CHICAGO, September 16, 2025--ClostraBio, Inc., a biotech company pioneering microbiome-based solutions for gastrointestinal health, today announced two major milestones: the appointment of Scott Ravech, former CEO of Deerland Probiotics & Enzymes, to its Board of Directors, and the peer-reviewed publication of toxicology data validating the safety of its lead ingredient, Anaerostipes caccae CLB101™. These achievements set the stage for the company’s commercial launch later this month with a lead",
    "url": "https://finnhub.io/api/news?id=b1866dd08e71dda61cc6ca5a22b9592b8da16f95e33f9dcf060910fd03cd4c39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758031200,
      "headline": "ClostraBio Announces Key Milestones: Board Appointment of Industry Veteran Scott Ravech and Publication of CLB101™ Safety Data",
      "id": 136773851,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ADM",
      "source": "Yahoo",
      "summary": "CHICAGO, September 16, 2025--ClostraBio, Inc., a biotech company pioneering microbiome-based solutions for gastrointestinal health, today announced two major milestones: the appointment of Scott Ravech, former CEO of Deerland Probiotics & Enzymes, to its Board of Directors, and the peer-reviewed publication of toxicology data validating the safety of its lead ingredient, Anaerostipes caccae CLB101™. These achievements set the stage for the company’s commercial launch later this month with a lead",
      "url": "https://finnhub.io/api/news?id=b1866dd08e71dda61cc6ca5a22b9592b8da16f95e33f9dcf060910fd03cd4c39"
    }
  }
]